Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
News|Articles|May 5, 2025
COA 2025: Insight, Innovation, and Independent Strength
Author(s)Maggie L. Shaw
The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.
Advertisement
Advertisement
The dual goals of the
Related to this article
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Advertisement
Advertisement